Skip to main content
. Author manuscript; available in PMC: 2018 Jun 22.
Published in final edited form as: Vaccine. 2017 May 26;35(29):3615–3620. doi: 10.1016/j.vaccine.2017.05.022

Figure 1. Robust anti-parvovirus B19 antibody forming cells (AFCs) and antibody responses follow VLP with MF59 immunization of mice with SCD.

Figure 1

Mice were vaccinated 3 times at 1 month intervals with either PBS (negative control), 5 μg VLP in PBS, 0.5 μg VLP in MF59, or 5 μg VLP in MF59 by the i.m. route. Three months after the first immunization, animals were sacrificed, and sera were tested for parvovirus B19 VLP-specific (A) IgG (all subtypes), (B) IgG1, and (C) IgG2B (N=4–5 animals per group). Clear and black bars represent heterozygous littermate controls (HET) and animals with SCD, respectively. Titers shown represent the dilution of sera that would produce an OD 405 reading of 0.1 within each assay. (D) Residual sera, when available, were also tested for neutralizing antibodies. Individual heterozygous and SCD are shown as open and solid symbols, respectively. The numbers of mice tested for neutralization in each group were as follows: 5 HETs and 2 SCD for PBS only; 5 HETs and 4 SCD for VLP in PBS; 4 HETs and 3 SCD for 0.5 μg VLP in MF59; 5 HETs and 5 SCD for 5 μg VLP in MF59. Samples failing to neutralize virus growth by 75% at the lowest dilution evaluated were assigned a titer of 100. Dotted lines indicate the lowest dilution of sera evaluated.